Contineum Therapeutics, Inc. (CTNM) shareholders
Close on Nov 16, 2026Market cap $363.80MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (7.90%) | 2,610,248 | 7.90% | 13G (passive) | Sep 30, 2026 |
| Janus Henderson Group PLC | 2,448,979 | 7.90% | 13G (passive) | Dec 31, 2025 |
| Dames GP LLC Joint filing with Balyasny Asset Management L.P. (7.40%), Bam Gp LLC (7.40%) and 2 more | 2,417,723 | 7.40% | 13G (passive) | Mar 31, 2026 |
| Balyasny Asset Management Holdings LP Joint filing with Balyasny Asset Management L.P. (7.14%), Bam Gp LLC (7.14%) and 2 more | 2,335,550 | 7.14% | 13G (passive) amendment | Jun 30, 2026 |
| Balyasny Asset Management L.P. Joint filing with Bam Gp LLC (7.60%), Balyasny Asset Management Holdings LP (7.60%) and 2 more | 2,312,800 | 7.60% | 13G (passive) | Dec 31, 2025 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (7.20%), Peter Kolchinsky (7.20%) and 1 more | 2,179,711 | 7.20% | 13G (passive) amendment | Dec 31, 2025 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more | 2,122,000 | 9.90% | 13G (passive) | Jul 18, 2025 |
| BlackRock, Inc. | 2,049,493 | 6.30% | 13G (passive) | Jun 30, 2026 |
| Johnson & Johnson Joint filing with Johnson & Johnson Innovation-JJDC, Inc. (10.70%) | 1,979,173 | 10.70% | 13G (passive) | Apr 9, 2024 |
| Johnson & Johnson Innovation - JJDC, Inc. Joint filing with Johnson & Johnson (5.60%) | 1,979,173 | 5.60% | 13G (passive) amendment | Nov 3, 2026 |
| Franklin Advisers, Inc. Joint filing with Franklin Resources, Inc. (6.20%) | 1,879,367 | 6.20% | 13G (passive) amendment | Dec 31, 2025 |
| Suvretta Capital Management, LLC Joint filing with Aaron Cowen (9.30%), Averill Master Fund, Ltd. (8.30%) | 1,720,000 | 9.30% | 13G (passive) | Apr 5, 2024 |
| Franklin Templeton, Inc. Joint filing with Franklin Advisers, Inc. (5.20%) | 1,704,550 | 5.20% | 13G (passive) amendment | Sep 30, 2026 |
| William Blank Joint filing with Squadron Master Fund LP (5.10%), Squadron Capital Management LLC (5.10%) and 1 more | 1,700,000 | 5.10% | 13G (passive) | Oct 21, 2026 |
| Franklin Resources, Inc. Joint filing with Franklin Advisers, Inc. (8.90%) | 1,698,825 | 8.90% | 13G (passive) amendment | Jun 30, 2025 |
| Ortav Yehudai Joint filing with Trails Edge Capital Partners, LP (5.10%), Trails Edge Biotechnology Master Fund, LP (5.10%) | 1,679,443 | 5.10% | 13G (passive) | Sep 22, 2026 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (5.10%), Israel A. Englander (5.10%) | 1,658,349 | 5.10% | 13G (passive) | Apr 13, 2026 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (5.60%), Perceptive Life Sciences Master Fund, Ltd. (5.60%) | 1,441,249 | 5.60% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CTNM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2,841,334 | 7.55% | $46.57M | – | 0.85% |
| Jupiter Topco LLC | 2,734,836 | 7.27% | $44.77M | New | 0.02% |
| BlackRock, Inc. | 2,064,345 | 5.49% | $33.83M | +1,395,222 | 0.00% |
| Johnson & Johnson | 1,979,173 | 5.26% | $32.44M | – | 4.06% |
| Franklin Resources Inc | 1,839,227 | 4.89% | $30.14M | – | 0.01% |
| Balyasny Asset Management L.P. | 1,522,793 | 4.05% | $24.96M | −162,842 | 0.03% |
| Vanguard Capital Management LLC | 1,321,356 | 3.51% | $21.66M | +107,183 | 0.00% |
| Perceptive Advisors LLC | 1,255,592 | 3.34% | $20.58M | – | 0.31% |
| FMR LLC | 1,040,130 | 2.76% | $17.05M | +225,259 | 0.00% |
| Millennium Management LLC | 931,709 | 2.48% | $15.27M | −603,740 | 0.01% |
| Great Point Partners LLC | 921,481 | 2.45% | $15.10M | +121,283 | 2.85% |
| Longaeva Partners L.P. | 812,757 | 2.16% | $13.32M | +80,669 | 0.29% |
| Ikarian Capital, LLC | 807,874 | 2.15% | $13.24M | – | 1.43% |
| Sectoral Asset Management Inc | 727,587 | 1.93% | $11.93M | – | 8.32% |
| Geode Capital Management, LLC | 693,188 | 1.84% | $11.36M | +411,150 | 0.00% |
| Hhlr Advisors, Ltd. | 669,337 | 1.78% | $10.97M | – | 1.32% |
| Red Tree Management, LLC | 638,158 | 1.70% | $10.46M | – | 7.10% |
| Versant Venture Management, LLC | 542,628 | 1.44% | $8.89M | – | 5.47% |
| Goldman Sachs Group Inc | 497,255 | 1.32% | $8.15M | +190,147 | 0.00% |
| Boxer Capital Management, LLC | 494,000 | 1.31% | $8.10M | – | 0.61% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 102 | 31M | 81.2% | 29 / 32 | 19 / 15 | 8M | 5M |
| Q1 2026 | 90 | 31M | 81.2% | 22 / 29 | 22 / 11 | 6M | 4M |
| Q4 2025 | 80 | 30M | 78.7% | 31 / 29 | 7 / 11 | 13M | 1M |
| Q3 2025 | 62 | 18M | 46.5% | 14 / 18 | 18 / 22 | 5M | 2M |
| Q2 2025 | 70 | 14M | 36.9% | 27 / 12 | 22 / 20 | 1M | 3M |
| Q1 2025 | 63 | 15M | 40.6% | 7 / 19 | 18 / 5 | 0M | 1M |
| Q4 2024 | 62 | 16M | 42.0% | 13 / 28 | 10 / 3 | 3M | 1M |
| Q3 2024 | 52 | 14M | 36.5% | 9 / 15 | 16 / 5 | 2M | 1M |
| Q2 2024 | 49 | 13M | 34.6% | 49 / 0 | 0 / 0 | 13M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
85 funds held CTNM in Q2 2026, 54% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CTNM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 982,259 | 2.61% | $16.10M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 646,661 | 1.72% | $10.60M | 0.01% | Jun 30, 2026 |
| Select Health Care Portfolio | 450,000 | 1.20% | $6.07M | 0.10% | May 31, 2026 |
| Franklin Biotechnology Discovery Fund | 330,090 | 0.88% | $5.11M | 0.44% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 308,749 | 0.82% | $5.06M | 0.01% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 295,058 | 0.78% | $4.57M | 0.40% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 294,824 | 0.78% | $4.57M | 0.01% | Jul 31, 2026 |
| Fidelity Advisor Health Care Fund | 280,000 | 0.74% | $4.34M | 0.14% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 244,589 | 0.65% | $4.01M | 0.03% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 224,900 | 0.60% | $3.48M | 0.16% | Jul 31, 2026 |
| iShares Biotechnology ETF | 205,163 | 0.55% | $3.36M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Stock Fund | 176,600 | 0.47% | $2.74M | 0.20% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 126,427 | 0.34% | $1.71M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 115,502 | 0.31% | $1.56M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 90,316 | 0.24% | $1.48M | 0.10% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Carmine N. Stengone | CEO and President, Director | 19,717 | 0.05% | Sep 8, 2026 |
| Daniel S. Lorrain | Chief Scientific Officer | 145,337 | 0.39% | Jul 10, 2026 |
| Tim Watkins | CMO & Head of Development | 8,961 | 0.02% | Jul 1, 2026 |
| John Stephen Healy | General Counsel and Corp Sec | – | – | Jan 30, 2026 |
| Peter T. Slover | Chief Financial Officer | – | – | Jan 30, 2026 |
| Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | 12,800 | 0.03% | Jan 31, 2025 |
| Troy A. Ignelzi | Director | – | – | Jun 26, 2026 |
| Evert B. Schimmelpennink | Director | – | – | Jun 26, 2026 |
| Gines Diego Miralles | Director | – | – | Jun 26, 2026 |
| Todd R. Brady | Director | – | – | Jun 26, 2026 |
| Sarah Boyce | Director | – | – | Jun 26, 2026 |
| Olivia C. Ware | Director | – | – | Jun 26, 2026 |
| Lori Lyons-Williams | Director | – | – | Jun 26, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Carmine N. Stengone CEO and President, Director | Sep 8, 2026 | Option exercise | +2,500 | $1.01 | $2.53K | 19,717 |
| Carmine N. Stengone CEO and President, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,500 | $16.46 | $41.15K | 17,217 |
| Carmine N. Stengone CEO and President, Director | Aug 3, 2026 | Option exercise | +2,500 | $1.01 | $2.53K | 19,717 |
| Carmine N. Stengone CEO and President, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −2,500 | $16.01 | $40.03K | 17,217 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 9, 2026 | Option exercise | +25 | $1.01 | $25 | 135,227 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 9, 2026 | Sale(10b5-1 plan) | −25 | $16.00 | $400 | 135,202 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 8, 2026 | Sale(10b5-1 plan) | −1,015 | $16.00 | $16.24K | 135,202 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 8, 2026 | Option exercise | +1,015 | $1.01 | $1.03K | 136,217 |
| Carmine N. Stengone CEO and President, Director | Jul 8, 2026 | Option exercise | +2,500 | $1.01 | $2.53K | 19,717 |
| Carmine N. Stengone CEO and President, Director | Jul 8, 2026 | Sale(10b5-1 plan) | −2,500 | $16.00 | $40.00K | 17,217 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 1, 2026 | Option exercise | +4,183 | $1.01 | $4.22K | 143,555 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −5,852 | $15.67 | $91.70K | 137,703 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −2,501 | $16.24 | $40.62K | 135,202 |
| Daniel S. Lorrain Chief Scientific Officer | Jun 30, 2026 | Option exercise | +28,826 | $1.01 | $29.11K | 168,198 |
| Daniel S. Lorrain Chief Scientific Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −28,826 | $16.04 | $462.37K | 139,372 |
| Carmine N. Stengone CEO and President, Director | Jun 30, 2026 | Option exercise | +2,500 | $1.26 | $3.15K | 27,217 |
| Carmine N. Stengone CEO and President, Director | Jun 30, 2026 | Option exercise | +7,500 | $1.01 | $7.58K | 24,717 |
| Carmine N. Stengone CEO and President, Director | Jun 30, 2026 | Sale(10b5-1 plan) | −10,000 | $16.01 | $160.10K | 17,217 |
| Tim Watkins CMO & Head of Development | Jun 30, 2026 | Sale(10b5-1 plan) | −10,833 | $16.02 | $173.54K | 8,961 |
| Tim Watkins CMO & Head of Development | Jun 30, 2026 | Option exercise | +10,833 | $4.50 | $48.75K | 19,794 |
| Daniel S. Lorrain Chief Scientific Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −4,170 | $13.16 | $54.88K | 139,372 |
| Daniel S. Lorrain Chief Scientific Officer | May 1, 2026 | Sale(10b5-1 plan) | −3,870 | $13.06 | $50.54K | 143,842 |
| Daniel S. Lorrain Chief Scientific Officer | May 1, 2026 | Sale(10b5-1 plan) | −300 | $13.84 | $4.15K | 143,542 |
| Daniel S. Lorrain Chief Scientific Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −4,170 | $13.43 | $56.00K | 147,712 |
| Daniel S. Lorrain Chief Scientific Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −4,170 | $15.01 | $62.59K | 151,882 |
| Tim Watkins CMO & Head of Development | Mar 2, 2026 | Sale(10b5-1 plan) | −3,611 | $15.02 | $54.24K | 0 |
| Tim Watkins CMO & Head of Development | Mar 2, 2026 | Option exercise | +3,611 | $4.50 | $16.25K | 3,611 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 25, 2026 | Option exercise | +3,824 | $1.01 | $3.86K | 159,876 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −3,824 | $16.01 | $61.22K | 156,052 |
| Carmine N. Stengone CEO and President, Director | Feb 25, 2026 | Sale(10b5-1 plan) | −2,700 | $16.02 | $43.25K | 14,954 |
| Carmine N. Stengone CEO and President, Director | Feb 25, 2026 | Option exercise | +2,700 | $1.26 | $3.40K | 17,654 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −4,300 | $16.03 | $68.93K | 156,052 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 24, 2026 | Option exercise | +4,300 | $1.01 | $4.34K | 160,352 |
| Carmine N. Stengone CEO and President, Director | Feb 24, 2026 | Sale(10b5-1 plan) | −4,400 | $16.02 | $70.49K | 14,954 |
| Carmine N. Stengone CEO and President, Director | Feb 24, 2026 | Option exercise | +4,400 | $1.26 | $5.54K | 19,354 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 19, 2026 | Option exercise | +100 | $1.01 | $101 | 156,152 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 19, 2026 | Sale(10b5-1 plan) | −100 | $16.00 | $1.60K | 156,052 |
| Carmine N. Stengone CEO and President, Director | Feb 11, 2026 | Sale(10b5-1 plan) | −400 | $16.00 | $6.40K | 14,954 |
| Carmine N. Stengone CEO and President, Director | Feb 11, 2026 | Option exercise | +400 | $1.26 | $504 | 15,354 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 11, 2026 | Sale(10b5-1 plan) | −400 | $16.00 | $6.40K | 156,052 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 11, 2026 | Option exercise | +400 | $1.01 | $404 | 156,452 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 3, 2026 | Sale(10b5-1 plan) | −1,170 | $15.25 | $17.84K | 156,052 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 3, 2026 | Sale(10b5-1 plan) | −3,000 | $14.82 | $44.46K | 157,222 |
| Tim Watkins CMO & Head of Development | Jan 28, 2026 | Sale(10b5-1 plan) | −811 | $14.48 | $11.74K | 0 |
| Tim Watkins CMO & Head of Development | Jan 28, 2026 | Option exercise | +3,611 | $4.50 | $16.25K | 3,611 |
| Tim Watkins CMO & Head of Development | Jan 28, 2026 | Sale(10b5-1 plan) | −2,800 | $14.09 | $39.45K | 811 |
| Daniel S. Lorrain Chief Scientific Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −500 | $11.13 | $5.57K | 160,222 |
| Daniel S. Lorrain Chief Scientific Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −3,670 | $10.35 | $37.98K | 160,722 |
| Tim Watkins CMO & Head of Development | Dec 29, 2025 | Option exercise | +3,611 | $4.50 | $16.25K | 3,611 |
| Tim Watkins CMO & Head of Development | Dec 29, 2025 | Sale(10b5-1 plan) | −3,611 | $12.06 | $43.55K | 0 |
| Daniel S. Lorrain Chief Scientific Officer | Dec 23, 2025 | Sale(10b5-1 plan) | −4,170 | $12.23 | $51.00K | 164,392 |
| Daniel S. Lorrain Chief Scientific Officer | Nov 25, 2024 | Sale(10b5-1 plan) | −1,010 | $16.02 | $16.18K | 168,562 |
| Daniel S. Lorrain Chief Scientific Officer | Nov 18, 2024 | Sale(10b5-1 plan) | −99 | $17.05 | $1.69K | 169,572 |
| Daniel S. Lorrain Chief Scientific Officer | Nov 18, 2024 | Sale(10b5-1 plan) | −6,091 | $16.37 | $99.71K | 169,671 |
| Stephen L. Huhn CMO & Sr VP, Clinical Dev. | Aug 13, 2024 | Option exercise | +12,800 | $1.01 | $12.93K | 12,800 |
| Versant Vantage I, L.P. 10% owner | Apr 9, 2024 | Conversion | +2,531 | – | – | 2,531 |
| Versant Vantage I, L.P. 10% owner | Apr 9, 2024 | Conversion | +148,312 | – | – | 148,312 |
| Versant Vantage I, L.P. 10% owner | Apr 9, 2024 | Conversion | +391,785 | – | – | 391,785 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Contineum Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,695 shares on Sep 15, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Daniel S. Lorrain Officer | Nov 4, 2026 | 4,170 | $40.41K | Nov 4, 2026 | Restricted Stock Units |
| Daniel S. Lorrain Officer | Oct 1, 2026 | 4,170 | $55.96K | Oct 1, 2026 | Restricted Stock Units |
| Carmine N. Stengone Director, Officer | Sep 8, 2026 | 2,500 | $41.75K | Sep 8, 2026 | Exercise of Stock Options |
| Daniel S. Lorrain Officer | Sep 1, 2026 | 9,520 | $154.60K | Sep 1, 2026 | Exercise of Stock Options |
| Carmine N. Stengone Director, Officer | Aug 3, 2026 | 2,500 | $38.73K | Aug 3, 2026 | Exercise of Stock Options |
| Daniel S. Lorrain Officer | Aug 3, 2026 | 9,520 | $147.46K | Aug 3, 2026 | Restricted Stock Units |
| Carmine N. Stengone Director, Officer | Jul 8, 2026 | 2,500 | $36.40K | Jul 8, 2026 | Exercise of Stock Options |
| Daniel S. Lorrain Officer | Jul 1, 2026 | 9,520 | $156.03K | Jul 1, 2026 | Exercise of Stock Options |
| Daniel S. Lorrain Officer | Jun 30, 2026 | 28,826 | $432.39K | Jun 30, 2026 | Exercise of Stock Options |
| Carmine N. Stengone Director, Officer | Jun 30, 2026 | 10,000 | $150.00K | Jun 30, 2026 | Exercise of Stock Options |
| Timothy Watkins Officer | Jun 30, 2026 | 10,833 | $162.50K | Jun 30, 2026 | Exercise of Stock Options |
| Daniel S. Lorrain Officer | Jun 1, 2026 | 4,170 | $56.25K | Jun 1, 2026 | Restricted Stock Units |
| Daniel S. Lorrain Officer | May 1, 2026 | 4,170 | $53.46K | May 1, 2026 | Restricted Stock Units |
| Daniel S. Lorrain Officer | Apr 6, 2026 | 914 | $12.28K | Apr 6, 2026 | Restricted Stock Units |
| Daniel S. Lorrain Officer | Feb 11, 2026 | 16,050 | $252.79K | Feb 11, 2026 | Exercise of Stock Options |
See a number that looks wrong?